SUBSTANTIATION OF SUBSTITUTION THERAPY MEDICATION FOR DRY EYE SYNDROME TREATMENT IN PATIENTS USING CONTACT LENS VISION CORRECTION.

Objective: The aim: To substantiate the selection of a substitution therapy medication for dry eye syndrome treatment in patients wearing different kinds of contact lenses.

Patients And Methods: Materials and methods: A structural analysis of the assortment of substitution therapy medications for dry eye syndrome treatment as well as a content analysis of the information given in the labelling claims of various substitution therapy medication was conducted. Than they were segmented using the criteria of whether the substitution therapy medications may be used in patients with dry eye syndrome who wear contact lenses.

Research of rheological properties of medicinal syrup for oral use.

Objective: The aim of the present research was to investigate the rheological properties of the medicinal syrup for oral administration with glucosamine hydrochloride and levocarnitine.

Patients And Methods: Matherials and methods: Coefficient of the dynamic flow (at shear rates of 3,49 and 10,3 s -1, as well as at shear rates of 27.2 and 149.

[The effect of electromagnetic field on the biosynthesis and various properties of extracellular proteinase and lectin from Bacillus subtilis 316 M].

The promoting effect of electromagnetic field (EMF) on biosynthesis and activity of extracellular proteinase and lectin in B. subtilis 316 M was observed. It caused 1.

[Effect of an electromagnetic field on subtilisin from Bacillus subtilis 316 m].

The influence of electromagnetic field on the subtilisin of Bacillus subtilis strain 316 M preparation has been studied. It is the increase 30-60% of the proteolytic activity during 60-100 min treatment was observed. The effect of activation is stable for a month at +4 degrees C.

[Characteristics of a beta-galactosidase substance obtained by an ultrafiltration method].

The ultrafiltration method with application of Vladipor membranes YAM-300 has been used to obtain 8.9 times purified preparation of beta-D-galactosidase (EC 3.2.